---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174506"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:43:42.071298+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months

## Summary
- Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.
- Expects $40-45M non-cash impairment on Bothell/Seattle facilities due to sublease plans and manufacturing shift.
- Raised $29.1M net proceeds via ATM sale of 7.44M shares between April 1 and August 6, 2025.
- UP421 trial meets all endpoints: transplanted beta cells survive, produce insulin, evade immune detection at 6 months.
- Sonja Schrepfer, SVP and Head of Hypoimmune Platform, resigned to pursue other opportunities.

## SEC filing metadata
- accession: 0001193125-25-174506
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312525174506/0001193125-25-174506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312525174506/d36055d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174506
- JSON: https://secwatch.observer/filing/0001193125-25-174506.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.